<DOC>
	<DOCNO>NCT00483626</DOCNO>
	<brief_summary>The purpose study determine clinical , functional hemodynamic response six month sildenafil 50 mg TID patient pulmonary arterial hypertension .</brief_summary>
	<brief_title>Hemodynamic Response After Six Months Sildenafil</brief_title>
	<detailed_description>Pulmonary arterial hypertension chronic devastate disease . There approval oral treatment . Sildenafil , phosphodiesterase 5 inhibitor , recently approve patient functional class II III show hemodynamic benefit 12 week treatment . Long term hemodynamic evaluation sildenafil treatment evaluate pulmonary arterial patient functional class II IV . The protocol design evaluate patient functional class II IV baseline condition 6 month sildenafil treatment ( 50 mg po TID ) . Clinical ( functional class ) , functional ( walked distance-6 minute walk test ) Hemodynamic evaluation plan perform baseline 6 month treatment .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Patients older 15 year old Pulmonary arterial hypertension accord WHO hemodynamic definition , Who sign informed consent , Able swallow tablet follow instruction . Patients pulmonary hypertension category pulmonary arterial hypertension ( associate COPD , lund disease , sleep apnea , thromboembolic disease , hight altitude ) , patient asymptomatic , patient responder adenosine hemodynamic test , patient treat specific treatment pulmonary arterial hypertension start study sildenafil , prostanoids , endothelin receptor blocker .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>hemodynamic</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>sildenafil</keyword>
</DOC>